Mouse Study Points to Neuronal ERBB4 as an Early Alzheimer’s Mechanism
Research in Alzheimer’s disease mouse models identified increased Erbb4 expression in excitatory neurons as an early change linked to network abnormalities, synapse loss, gliosis, plaque deposition and cognitive deficits. Human transcriptomic analysis was consistent with a possible pathogenic role, but the findings remain preclinical and do not establish that ERBB4 drives Alzheimer’s disease in people.
A study in Alzheimer’s disease mouse models identifies abnormal ERBB4 expression in excitatory neurons as a possible early driver of disease-like changes, while transcriptomic analysis of human Alzheimer’s data provides additional support for the proposed mechanism. The research, linked by Fight Aging! to a paper in Nature, also points to mammalian target of rapamycin (mTOR) signaling as part of the process.
Using single-nucleus RNA sequencing, the researchers identified a population they called early-responsive excitatory neurons, or EREN. These neurons emerged among the earliest major alterations in the Alzheimer’s mouse models and were characterized by ectopic expression of Erbb4, the mouse form of the gene encoding ERBB4.
The team then manipulated Erbb4 in excitatory neurons. Selectively deleting the gene in the Alzheimer’s models prevented several disease-like outcomes, including abnormal neuronal network activity, synapse loss, reactive gliosis, amyloid plaque deposition and cognitive deficits, according to the study summary.
The opposite manipulation produced a different kind of test. Increasing Erbb4 expression in excitatory neurons of otherwise typical mice recreated core Alzheimer’s-like features, although it did so without producing amyloid plaques. The findings indicate that elevated Erbb4 was sufficient to reproduce some of the measured abnormalities in this model, but they do not show that the same intervention causes Alzheimer’s disease in humans.
Additional transcriptomic analyses suggested that excitatory-neuron Erbb4 was both necessary and sufficient for inducing the EREN state and reactive gliosis in the experimental systems. The researchers reported that these effects depended on mTOR signaling downstream of ERBB4, identifying a possible molecular pathway connecting the altered receptor expression to the observed changes.
The study also examined human Alzheimer’s transcriptomic data. A directed mediation analysis supported a model in which excitatory-neuron ERBB4 may participate in a cascade linking amyloid pathology with tau propagation and cognitive decline. That analysis is compatible with the proposed mechanism, but it remains evidence from gene-expression data rather than a human intervention study demonstrating causation.
Fight Aging! cautioned that the mouse models used for this type of research are artificial. Mice do not ordinarily develop the human form of Alzheimer’s disease, and researchers must induce dysfunction that resembles aspects of the condition. As a result, the assumptions built into the models may not fully represent the mechanisms operating in human disease.
The findings therefore position aberrant ERBB4 expression as a potential research target in Alzheimer’s disease and possibly other neurodegenerative conditions, rather than as an established treatment mechanism. The work was reported on September 4, 2026, and is available through the DOI 10.1038/s41586-026-10964-z.
Reporting Note
Biohack Report distinguishes preliminary findings, clinical evidence and commercial claims whenever the available reporting supports that distinction. Coverage is informational and is not medical advice.